Cao Y, Hayashi C, Kumar N
J Infect Dis. 2024; 229(6):1894-1903.
PMID: 38408353
PMC: 11175679.
DOI: 10.1093/infdis/jiae102.
Rodriguez-Hernandez A, Martinez-Flores D, Cruz-Resendiz A, Padilla-Flores T, Gonzalez-Flores R, Estrada K
Viruses. 2023; 15(2).
PMID: 36851625
PMC: 9962271.
DOI: 10.3390/v15020411.
Cao Y, Hayashi C, Zavala F, Tripathi A, Simonyan H, Young C
Vaccines (Basel). 2022; 10(7).
PMID: 35891298
PMC: 9323668.
DOI: 10.3390/vaccines10071134.
Huang W, Deng B, Mabrouk M, Seffouh A, Ortega J, Long C
Malar J. 2020; 19(1):309.
PMID: 32859199
PMC: 7453371.
DOI: 10.1186/s12936-020-03368-5.
Parzych E, Miura K, Long C, Burns Jr J
PLoS One. 2020; 15(4):e0232355.
PMID: 32348377
PMC: 7190115.
DOI: 10.1371/journal.pone.0232355.
Characterization of Plasmodium berghei Homologues of T-cell Immunomodulatory Protein as a New Potential Candidate for Protecting against Experimental Cerebral Malaria.
Cui A, Li Y, Zhou X, Wang L, Luo E
Korean J Parasitol. 2019; 57(2):101-115.
PMID: 31104402
PMC: 6526220.
DOI: 10.3347/kjp.2019.57.2.101.
A malaria vaccine adjuvant based on recombinant antigen binding to liposomes.
Huang W, Deng B, Lin C, Carter K, Geng J, Razi A
Nat Nanotechnol. 2018; 13(12):1174-1181.
PMID: 30297818
PMC: 6286227.
DOI: 10.1038/s41565-018-0271-3.
Baculovirus Surface Display of Immunogenic Proteins for Vaccine Development.
Premanand B, Zhong Wee P, Prabakaran M
Viruses. 2018; 10(6).
PMID: 29857561
PMC: 6024371.
DOI: 10.3390/v10060298.
Acceptability of a herd immunity-focused, transmission-blocking malaria vaccine in malaria-endemic communities in the Peruvian Amazon: an exploratory study.
White S, Harvey S, Meza G, Llanos A, Guzman M, Gamboa D
Malar J. 2018; 17(1):179.
PMID: 29703192
PMC: 5921293.
DOI: 10.1186/s12936-018-2328-z.
Adenovirus-prime and baculovirus-boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model.
Yoshida K, Iyori M, Blagborough A, Salman A, Dulal P, Sala K
Sci Rep. 2018; 8(1):3896.
PMID: 29497047
PMC: 5832798.
DOI: 10.1038/s41598-018-21369-y.
DAF-shielded baculovirus-vectored vaccine enhances protection against malaria sporozoite challenge in mice.
Iyori M, Yamamoto D, Sakaguchi M, Mizutani M, Ogata S, Nishiura H
Malar J. 2017; 16(1):390.
PMID: 28962615
PMC: 5622557.
DOI: 10.1186/s12936-017-2039-x.
Rhesus macaque and mouse models for down-selecting circumsporozoite protein based malaria vaccines differ significantly in immunogenicity and functional outcomes.
Phares T, May A, Genito C, Hoyt N, Khan F, Porter M
Malar J. 2017; 16(1):115.
PMID: 28288639
PMC: 5347822.
DOI: 10.1186/s12936-017-1766-3.
Development of a Plasmodium berghei transgenic parasite expressing the full-length Plasmodium vivax circumsporozoite VK247 protein for testing vaccine efficacy in a murine model.
Mizutani M, Fukumoto S, Soubeiga A, Soga A, Iyori M, Yoshida S
Malar J. 2016; 15(1):251.
PMID: 27129682
PMC: 4851775.
DOI: 10.1186/s12936-016-1297-3.
Characterization of a Plasmodium berghei sexual stage antigen PbPH as a new candidate for malaria transmission-blocking vaccine.
Kou X, Zheng W, Du F, Liu F, Wang M, Fan Q
Parasit Vectors. 2016; 9:190.
PMID: 27038925
PMC: 4818878.
DOI: 10.1186/s13071-016-1459-8.
Alga-produced malaria transmission-blocking vaccine candidate Pfs25 formulated with a human use-compatible potent adjuvant induces high-affinity antibodies that block Plasmodium falciparum infection of mosquitoes.
Patra K, Li F, Carter D, Gregory J, Baga S, Reed S
Infect Immun. 2015; 83(5):1799-808.
PMID: 25690099
PMC: 4399074.
DOI: 10.1128/IAI.02980-14.
Baculovirus-vectored multistage Plasmodium vivax vaccine induces both protective and transmission-blocking immunities against transgenic rodent malaria parasites.
Mizutani M, Iyori M, Blagborough A, Fukumoto S, Funatsu T, Sinden R
Infect Immun. 2014; 82(10):4348-57.
PMID: 25092912
PMC: 4187867.
DOI: 10.1128/IAI.02040-14.
Protective efficacy of baculovirus dual expression system vaccine expressing Plasmodium falciparum circumsporozoite protein.
Iyori M, Nakaya H, Inagaki K, Pichyangkul S, Yamamoto D, Kawasaki M
PLoS One. 2013; 8(8):e70819.
PMID: 23951015
PMC: 3741388.
DOI: 10.1371/journal.pone.0070819.
Baculovirus as a vaccine vector.
Lu H, Chen Y, Liu H
Bioengineered. 2012; 3(5):271-4.
PMID: 22705893
PMC: 3477694.
DOI: 10.4161/bioe.20679.
Algae-produced Pfs25 elicits antibodies that inhibit malaria transmission.
Gregory J, Li F, Tomosada L, Cox C, Topol A, Vinetz J
PLoS One. 2012; 7(5):e37179.
PMID: 22615931
PMC: 3353897.
DOI: 10.1371/journal.pone.0037179.
A viral vectored prime-boost immunization regime targeting the malaria Pfs25 antigen induces transmission-blocking activity.
Goodman A, Blagborough A, Biswas S, Wu Y, Hill A, Sinden R
PLoS One. 2012; 6(12):e29428.
PMID: 22216279
PMC: 3247263.
DOI: 10.1371/journal.pone.0029428.